PPHMP Stock UPDATES Peregrine Pharmaceuticals Inc. (PPHMP) 23.75

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Peregrine Pharmaceuticals Inc. (PPHMP) 23.75 $PPHMP

Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection
Marketwired - Wed Oct 15, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the publication of a peer-reviewed manuscript related to preclinical research demonstrating that the company's lead drug candidate bavituximab, a phosphatidylserine (PS)-targeting antibody, exhibits specific and strong binding to Ebola virions and Ebola virus (EBOV)-infected cells in vitro. These results will appear in the Vaccines and Therapies for Biodefense Agents special edition of the peer-reviewed Journal of Immunology Research in a manuscript titled: "Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions."
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment
Marketwire - Mon Oct 06, 7:03AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of preclinical data related to the company's immuno-oncology development program and its lead drug candidate bavituximab, a phosphatidylserine (PS)-targeting antibody. Data show that PS-targeting agents in combination with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4, promote a robust and localized anti-tumor response in models of melanoma and breast cancer and decrease levels of myeloid derived suppressor cells (MDSC) in the tumor microenvironment. Newly generated data show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression compared to anti-PD-1 antibody treatment alone in an animal model of melanoma. These data will be presented this morning at the Cancer Research Institutes' "Cancer Immunotherapy: Out of the Gate" conference being held at the Grand Hyatt Hotel in New York, New York.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments
Marketwire - Tue Sep 09, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the first quarter of fiscal year (FY) 2015 ended July 31, 2014 and provided an update on its advancing clinical pipeline led by its investigational immuno-oncology candidate bavituximab and reviewed other corporate developments.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwire - Mon Sep 08, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock" .
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014
Marketwire - Tue Sep 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter fiscal year (FY) 2015 ended July 31, 2014 on September 9, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Marketwire - Mon Aug 11, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announces preclinical data further validating the potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform. Results show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression while also demonstrating a significant increase in tumor-fighting T-cells into the tumor microenvironment compared to anti-PD-1 antibody treatment alone in an immune competent animal model of breast cancer. These data will be presented today at 12:00 PM EDT at ImVacS, the 9th Annual Immunotherapies and Vaccine Summit being held August 11-14, 2014 in Boston, Massachusetts. Bavituximab is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Mon Jul 14, 3:01PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the fourth quarter and the fiscal year (FY) 2014 ended April 30, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014
Marketwire - Mon Jul 07, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the fourth quarter and fiscal year (FY) 2014 ended April 30, 2014 on July 14, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the fourth quarter ended April 30, 2014 of FY 2014 and will review recent progress of its clinical development programs.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Marketwire - Tue Apr 01, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 5-9, 2014 in San Diego, California. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with irradiation as well as with approved and developmental cancer immunotherapies.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Marketwire - Fri Mar 14, 7:01AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of an update to the ongoing Investigator-Sponsored Trial (IST) of its immunotherapy bavituximab in combination with the chemotherapy sorafenib (Nexavar(R)) in patients with advanced hepatocellular carcinoma (HCC) or liver cancer. The oral presentation was given at the 67th Society of Surgical Oncology (SSO) Annual Cancer Symposium being held March 12-15, 2014 at the Phoenix Convention Center in Phoenix, Arizona.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies
Marketwire - Thu Mar 13, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine (PS)-targeting antibodies in both oncology and antiviral therapeutic areas. These data were detailed in presentations at the Keystone Immune Evolution in Cancer symposium in Whistler, British Columbia, Canada and the Keystone HIV Pathogenesis - Virus vs. Host symposium in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies
Marketwire - Tue Mar 11, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presentations made validate the immune-stimulatory mechanism of its phosphatidylserine (PS) targeting platform while demonstrating that the combination of an anti-PS antibody and anti-CTLA-4 or anti-PD-1 antibody displayed superior tumor growth than either anti-CTLA-4 or anti-PD-1 antibody alone in animal tumor models. These data were outlined in two presentations at the Keystone Immune Evolution in Cancer meeting being held March 9-13, 2014 in Whistler, British Columbia, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)

Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Fri Mar 07, 7:01AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the third quarter of fiscal year (FY) 2014 ended January 31, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
PPHMP: 23.75 (-0.04), PPHM: 1.48 (-0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 13

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 75

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 147

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 170

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 111

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 40

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 87

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 52

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading

Top 5 Most Recently Viewed Articles

boberdoo Launches Dynamic Consent for Enhanced User Privacy

Updated Category News Views 92

boberdoo's Innovative Approach to One-to-One Consent boberdoo is making waves with its Dynamic Consent solution, a vital tool for businesses looking to comply with the FCC's one-to-one consent regulation. This live solution has been available since May 2024 and is designed to enhance transparency in lead generation by allowing consumers to have a voice in which companies...

Continue Reading
Understanding the Recent Private Student Loan Trends and Insights

Updated Category News Views 254

Overview of Recent Trends in Private Student Loans In the recent semi-annual Private Student Loan Report released by Enterval Analytics, insights into the current status of private student loans reveal a stable repayment landscape. Since Enterval focuses on the private student loan market, their findings shed light on how borrowers are adapting their financial strategies...

Continue Reading
Kyocera Unveils Exclusive Knife Set Celebrating 40 Years of Innovation

Updated Category News Views 62

Kyocera celebrated four decades of pushing boundaries in ceramic cutlery, revealing an exclusive two-piece knife set designed for both chefs and home cooks. The knives—a 4.5-inch Utility and a 5.5-inch Santoku—come dressed in vibrant Aegean Blue or Botanical Green and carry a price tag of $85. This limited-edition release is set to hit select retailers by late fall...

Continue Reading
PTC Plans Conference Call for Upcoming Fiscal Q1 Results

Updated Category News Views 145

PTC to Hold Fiscal Q1 Conference Call Boston, January 2026 — PTC (NASDAQ: PTC) is gearing up to unveil its financial performance for the first quarter of fiscal year 2026 on February 4. Investors and interested parties are invited to join a conference call and webcast at 5 PM Eastern Time, right after the stock market closes. This event will provide valuable insights...

Continue Reading
Moke America Unveils Enhanced Electric Street Vehicle for All

Updated Category News Views 282

Introducing the New Electric Street-Legal Moke Moke America, the beloved electric vehicle manufacturer, has taken a bold step forward with the launch of its latest street-legal Moke. Previously classified as a Low Speed Vehicle, this newly upgraded Moke can now reach an impressive top speed of 45 MPH, transforming the driving experience into something truly exhilarating....

Continue Reading